Replimune Group, Inc. NASDAQ:REPL

Founder-led company

Replimune Group stock price today

$5.26
-7
-57.1%
Financial Health
0
1
2
3
4
5
6
7
8
9

Replimune Group stock price monthly change

+18.34%
month

Replimune Group stock price quarterly change

+18.34%
quarter

Replimune Group stock price yearly change

+49.70%
year

Replimune Group key metrics

Market Cap
944.39M
Enterprise value
781.76M
P/E
-5.9
EV/Sales
N/A
EV/EBITDA
-5.12
Price/Sales
N/A
Price/Book
1.55
PEG ratio
0.20
EPS
N/A
Revenue
N/A
EBITDA
-170.03M
Income
-165.68M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Replimune Group stock price history

Replimune Group stock forecast

Replimune Group financial statements

Average Price Target
Last Year

$19

Potential upside: 261.21%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Replimune Group, Inc. (NASDAQ:REPL): Profit margin
Dec 2021 0 -29.67M
Mar 2022 0 -31.69M
Mar 2023 0 -49.23M
Mar 2024 0 -55.07M
Replimune Group, Inc. (NASDAQ:REPL): Debt to assets
Sep 2022 436095000 52.02M 11.93%
Dec 2022 678550000 83.20M 12.26%
Mar 2023 646591000 91.29M 14.12%
Mar 2024 487722000 113.21M 23.21%
Replimune Group, Inc. (NASDAQ:REPL): Cash Flow
Dec 2021 -18.34M -13.42M 3.96M
Mar 2022 -22.55M -4.32M 359K
Mar 2023 -32.79M -22.75M -77K
Mar 2024 -46.16M 23.20M -130K

Replimune Group alternative data

Replimune Group, Inc. (NASDAQ:REPL): Employee count
Sep 2023 284
Oct 2023 284
Nov 2023 284
Dec 2023 284
Jan 2024 284
Feb 2024 284
Mar 2024 284
Apr 2024 284
May 2024 284
Jun 2024 331
Jul 2024 331

Replimune Group other data

27.53% -60.45%
of REPL is owned by hedge funds
15.92M -32.25M
shares is hold by hedge funds

Replimune Group, Inc. (NASDAQ:REPL): Insider trades (number of shares)
Period Buy Sel
May 2024 0 98084
Jun 2024 0 15881
Aug 2024 0 8938
Nov 2024 0 12453
Dec 2024 0 10000
Transaction Date Insider Security Shares Price per share Total value Source
Sale
PATEL SUSHIL director, officer: Chief Execut..
Common Stock 10,000 $12.42 $124,200
Sale
XYNOS KONSTANTINOS officer: Chief Medical Officer
Common Stock 7,246 $10.78 $78,112
Sale
SARCHI CHRISTOPHER officer: Chief Commercial Officer
Common Stock 5,207 $10.78 $56,131
Sale
HILL EMILY LUISA officer: Chief Fi.. Common Stock 8,938 $10.18 $90,989
Sale
XYNOS KONSTANTINOS officer: Chief Medical Officer
Common Stock 15,881 $7.5 $119,108
Sale
SARCHI CHRISTOPHER officer: Chief Commercial Officer
Common Stock 2,218 $6.47 $14,350
Sale
SCHWENDENMAN ANDREW officer: Chief Accounting Officer
Common Stock 2,298 $6.47 $14,868
Sale
LOVE COLIN officer: Chief Operating Officer
Common Stock 17,615 $6.47 $113,969
Sale
ASTLEY-SPARKE PHILIP director, officer: Executive Ch..
Common Stock 37,928 $6.47 $245,394
Sale
COFFIN ROBERT director Common Stock 11,464 $6.47 $74,172
Insider Compensation
Dr. Robert Coffin Ph.D. (1965) Founder, Pres, Chief R&D Officer and Director $759,520
Mr. Philip Astley-Sparke FSA (1971) Chief Executive Officer & Director
$759,520
Ms. Tanya N. Lewis M.S. (1971) Chief Devel. Operations Officer
$16,230
Monday, 23 December 2024
globenewswire.com
Friday, 29 November 2024
seekingalpha.com
Monday, 25 November 2024
globenewswire.com
globenewswire.com
Friday, 22 November 2024
zacks.com
Thursday, 21 November 2024
globenewswire.com
Saturday, 9 November 2024
globenewswire.com
Friday, 8 November 2024
globenewswire.com
Wednesday, 30 October 2024
globenewswire.com
Wednesday, 9 October 2024
globenewswire.com
Monday, 7 October 2024
gurufocus.com
Sunday, 15 September 2024
globenewswire.com
Tuesday, 3 September 2024
seekingalpha.com
Tuesday, 13 August 2024
globenewswire.com
Tuesday, 30 July 2024
globenewswire.com
Friday, 7 June 2024
zacks.com
globenewswire.com
Thursday, 6 June 2024
globenewswire.com
Monday, 3 June 2024
globenewswire.com
Thursday, 23 May 2024
globenewswire.com
Thursday, 16 May 2024
globenewswire.com
Sunday, 7 April 2024
globenewswire.com
Thursday, 4 April 2024
globenewswire.com
Tuesday, 26 March 2024
globenewswire.com
Monday, 11 March 2024
Zacks Investment Research
Friday, 8 March 2024
Zacks Investment Research
Friday, 23 February 2024
Zacks Investment Research
Thursday, 28 December 2023
GlobeNewsWire
Tuesday, 5 December 2023
InvestorPlace
Market Watch
  • What's the price of Replimune Group stock today?

    One share of Replimune Group stock can currently be purchased for approximately $5.26.

  • When is Replimune Group's next earnings date?

    Unfortunately, Replimune Group's (REPL) next earnings date is currently unknown.

  • Does Replimune Group pay dividends?

    No, Replimune Group does not pay dividends.

  • How much money does Replimune Group make?

    Replimune Group has a market capitalization of 944.39M.

  • What is Replimune Group's stock symbol?

    Replimune Group, Inc. is traded on the NASDAQ under the ticker symbol "REPL".

  • What is Replimune Group's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Replimune Group?

    Shares of Replimune Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Replimune Group's key executives?

    Replimune Group's management team includes the following people:

    • Dr. Robert Coffin Ph.D. Founder, Pres, Chief R&D Officer and Director(age: 60, pay: $759,520)
    • Mr. Philip Astley-Sparke FSA Chief Executive Officer & Director(age: 54, pay: $759,520)
    • Ms. Tanya N. Lewis M.S. Chief Devel. Operations Officer(age: 54, pay: $16,230)
  • Is Replimune Group founder-led company?

    Yes, Replimune Group is a company led by its founder Dr. Robert Coffin Ph.D..

  • How many employees does Replimune Group have?

    As Jul 2024, Replimune Group employs 331 workers, which is 17% more then previous quarter.

  • When Replimune Group went public?

    Replimune Group, Inc. is publicly traded company for more then 7 years since IPO on 20 Jul 2018.

  • What is Replimune Group's official website?

    The official website for Replimune Group is replimune.com.

  • Where are Replimune Group's headquarters?

    Replimune Group is headquartered at 500 Unicorn Park Drive, Woburn, MA.

  • How can i contact Replimune Group?

    Replimune Group's mailing address is 500 Unicorn Park Drive, Woburn, MA and company can be reached via phone at +7 812229600.

  • What is Replimune Group stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for Replimune Group in the last 12 months, the avarage price target is $19. The average price target represents a 261.21% change from the last price of $5.26.

Replimune Group company profile:

Replimune Group, Inc.

replimune.com
Exchange:

NASDAQ

Full time employees:

331

Industry:

Biotechnology

Sector:

Healthcare

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

500 Unicorn Park Drive
Woburn, MA 01801

CIK: 0001737953
ISIN: US76029N1063
CUSIP: 76029N106